MYO1B and prostate cancer: Our previous studies revealed that tumor-suppressive miR-145-3p was closely involved in human cancer pathogenesis by targeting oncogenes, for example, MTDH in LUSQ; MELK, NCAPG, BUB1, and CDK1 in prostate cancer; MYO1B in head and neck cancer; and MYO1B and DHRS2 in esophageal cancer [19,30,31,32].